Reversible nonoliguric acute renal failure associated with zomepirac therapy.
Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology / Q000652:urine; D000368:Aged; D000700:Analgesics / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D011758:Pyrroles / Q000009:adverse effects*; D014046:Tolmetin / Q000009:adverse effects* / Q000031:analogs & derivatives
D000700:Analgesics; D011758:Pyrroles; C020549:zomepirac; D003404:Creatinine; D014046:Tolmetin